{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-003880","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.944613+00:00","generated_at":"2026-06-28T00:30:43.775589+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Chemomab CEO Dale Pfost expected to become chairman; Stephen Squinto resigns as chairman and director","bullets":["Stephen Squinto resigns as chairman and director effective Dec 19, 2021; decision not due to any disagreement with company.","CEO Dale Pfost, PhD expected to become chairman subject to shareholder vote in or around February 2022.","Planned succession; Squinto's term was set to lapse by June 2022; transition accelerated to Dec 2021.","Company advancing Phase 2 programs in primary sclerosing cholangitis, liver fibrosis; Phase 2 trial in systemic sclerosis planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-003880","json":"https://secwatch.observer/filing/0001178913-21-003880.json","markdown":"https://secwatch.observer/filing/0001178913-21-003880.md","text":"https://secwatch.observer/filing/0001178913-21-003880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/0001178913-21-003880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T00:30:43.775589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71d5b5b339","claim":"Stephen Squinto resigned as Chairman of the Board at Chemomab Therapeutics Ltd..","evidence_excerpt":"On December 12, 2021, the Company and Mr. Squinto mutually agreed that Mr. Squinto’s resignation as the chairman of the Board will enter into effect on December 19, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/0001178913-21-003880-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"e16c816b1b","claim":"Dale Pfost was appointed as Chairman of the Board at Chemomab Therapeutics Ltd..","evidence_excerpt":"the nominating and governance committee and the Board each approved and recommended that the shareholders approve the appointment of Dr. Pfost as chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/0001178913-21-003880-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}